Search
Ammonium chloride
go.drugbank.com/drugs/DB06767ApprovedInvestigationalVet approvedAmmonium chloride is an inorganic compound with the formula NH4Cl. It is highly soluble in water producing mildly acidic solutions.
Mixtures: ELETTROLITICA EQUILIBRATA GASTRICA CON GLUCOSIO, ELETTROLITICA EQUILIBRATA GASTRICA CON GLUCOSIOIbandronate
go.drugbank.com/drugs/DB00710ApprovedInvestigational[L13805,L13808] Ibandronate was first described in the literature in 1993 as a treatment for bone loss in dogs.[A203138] Ibandronate was granted FDA approval on 16 May 2003.[L13805]
Categories: Bone Density Conservation Agents, Drugs for Treatment of Bone DiseasesProducts: BONDRONAT 6MG KON HER INF, ICIN KON. COZ. ICEREN FLAKONDesloratadine
go.drugbank.com/drugs/DB00967ApprovedInvestigationalDesloratadine is a second generation, tricyclic antihistamine that which has a selective and peripheral H1-antagonist action. It is the active descarboethoxy metabolite of loratidine (a second generation histamine). Desloratidine has a l...
Mixtures: BUCOXOL ® GRIP MAX CAPSULAS DURAS CON CONTENIDO LIQUIDO, BUCOXOL ® GRIP MAX CAPSULAS DURAS CON CONTENIDO LIQUIDOCategories: Histamine H1 Antagonists, Non-SedatingPipotiazine
go.drugbank.com/drugs/DB01621ApprovedInvestigationalWithdrawnIt is used for the maintenance treatment of chronic non-agitated schizophrenic patients. Symptoms of overdose include severe extrapyramidal manifestations, hypotension, lethargy and sedation.
Darolutamide
go.drugbank.com/drugs/DB12941ApprovedInvestigationalDarolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). … [A189054,A189063] Darolutamide was developed by Bayer HealthCare Pharmaceuticals Inc. and approved by the FDA on July 30th, 2019.[L10887]
Categories: Antiandrogens, non-steroidalCaplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression
Categories: von Willebrand Factor (vWF)-directed Antibodies, von Willebrand Factor, antagonists & inhibitorsGallium nitrate
go.drugbank.com/drugs/DB05260ApprovedInvestigational[A260816] Gallium nitrate is reported to possess antiresorptive and hypocalcemic effects on bone.
Categories: Bone Resorption InhibitionRomosozumab
go.drugbank.com/drugs/DB11866ApprovedInvestigationalRomosozumab prevents bone resorption and induces the formation of bone though it is associated with an increased risk of cardiac death, heart attack, and stroke in one study[L5921,L5924]. … Romosozumab also demonstrates a faster and larger increase in bone density than teriparatide[A177050]. Romosozumab is marketed in the United States by Amgen under the brand name Evinity[L5921].
Categories: Bone Anabolic Agents, Drugs for Treatment of Bone DiseasesTepotinib
go.drugbank.com/drugs/DB15133ApprovedInvestigationalTepotinib was first approved in Japan in March 2020 for the treatment of non-small cell lung cancers (NSCLC) with _MET_ alterations, and was subsequently granted accelerated approval by the US FDA in February … Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma,[A228053] gastric cancers,[A228033] non-small cell lung cancer, and hepatocellular carcinoma.
Tiaprofenic acid
go.drugbank.com/drugs/DB01600ApprovedTiaprofenic acid is a non-steroidal anti-inflammatory drug employed in the treatment of pain, particularly arthritis pain.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic